Johnson and Johnson Darzalex reduces risk of death in new myeloma patients by 40%

S. -- Johnson and Johnson has had no problems persuading doctors to use the multiple myeloma drug Darzalex, which quickly gained a sensational status with the support of some historic approvals. But the company said monday's new "gold-based" data could further boost doctors' confidence in medicine.
In a phase III study of previously untreated myeloma patients, adding Darzalex to a combined drug in Mifalon, Pernisson and Takeda reduced the risk of death by 40 percent, Johnson and Johnson's Jean Sang said at the annual meeting of the American Society of Hematology.
In the 42-month trial, known as Alkuonje, 75 percent of Darzalex patients were still alive, compared with 62 percent who received treatment without the drug J.J.
Related: Johnson and Johnson's Darzalex gets landmark myeloma approval in front-line patientsAdding Darzalex also helps prevent patients from getting worse; cocktails including Darzalex can suppress the disease in 36.4 months, while the American Fallon-Penison-Wilkaid triple group is 19.3 months.
“ In many ways, Alkuone's data is a watershed," said Mark Wilders, vice president of global medical affairs at Jean-San Oncology. "We have now shown that when we use daratumumab, we see survival benefits. That's what I think the medical community has been waiting for. This
, this does not mean that the doctor did not prescribe daratumumab during this period. The drug gave two green light to newly diagnosed patients, helping sales climb to $2.17 billion in the first nine months of 2019.
"Overall survival is the gold-based position we want to see, to confirm that when you start with your best broker, you actually get the best results," Verdegas said.
At the same time, because of Darzalex's performance at Alcyone, the company's most sophisticated trial in a front-line environment, the company has reason to believe that it can produce similar results in other trials involving newly diagnosed patients.
Related: Johnson and Johnson's Darzalex launches a best-selling product among new patients, while also launching a myeloma drugfor example, Maya's research helped Johnson and Johnson get Darzalex in June among patients who did not qualify for a transplant Revlimi and Desamisson, who also acquired Selkin, have shown, like Alcyone, the significant benefits of progressive survival and the benefits of whole gastrointestinal nutrition2, which shows how long second-line post-treatment can delay the disease.
"The longer we wait, the more mature it becomes, and we may also see survival in these studies," Wilders said.Johnson and Johnson certainly hope so. "The real opportunity to potentially improve patient prognosis is to treat newly diagnosed patients," Verdegas said. ”（cyy123.com）